Sulaiman Abdur-Rahman

Sulaiman Abdur-Rahman

Sulaiman Abdur-Rahman is a Litigation Reporter at ALM covering antitrust complaints, federal judicial nominations and legal matters in the Washington, D.C., metro area. He’s an alumnus of Temple University and longtime journalist who previously worked for publications in Pennsylvania and New Jersey. He also performed writing gigs at Babson College and SoFi Technologies Inc. before joining ALM in 2024.

Connect with this author

November 21, 2024 | National Law Journal

Read the Document: 'Google Must Divest Chrome,' DOJ Says, Proposing Remedies in Search Monopoly Case

"Google must promptly and fully divest Chrome" by selling the browser to a buyer approved by the Justice Department and state attorneys general, U.S. attorneys wrote in a proposed final judgment filed in District of Columbia federal court. " Google may elect to fully divest Android."

By Sulaiman Abdur-Rahman

3 minute read

November 19, 2024 | International Edition

US Lawsuit Seeks Damages from Iran for Role in Oct. 7 Attack on Israel

The United States has designated Iran a “state sponsor of terrorism” since January 1984, exposing Iran to potential liability under the state sponsor of terrorism exception to the Foreign Sovereign Immunities Act.

By Sulaiman Abdur-Rahman

3 minute read

November 19, 2024 | National Law Journal

Attorneys Go to DC Federal Court Seeking Damages for Plaintiffs in Oct. 7, 2023, Attack on Israel

The United States has designated Iran a “state sponsor of terrorism” since January 1984, exposing Iran to potential liability under the state sponsor of terrorism exception to the Foreign Sovereign Immunities Act.

By Sulaiman Abdur-Rahman

3 minute read

November 18, 2024 | National Law Journal

'Nuclear Option'?: Eli Lilly Taps Big Law Firms in Federal Drug Pricing Dispute

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program but also Medicaid and Medicare Part B if manufacturers implement a cash replenishment model,” counsel for Eli Lilly—the manufacturer of Mounjaro, Trulicity and other treatments for weight loss or diabetes—alleged in their complaint.

By Sulaiman Abdur-Rahman

3 minute read

November 15, 2024 | National Law Journal

Baltimore City Govt., After Winning Opioid Jury Trial, Preparing to Demand an Additional $11B for Abatement Costs

Susman Godfrey partner Bill Carmody said the $266 million “verdict was an important step toward helping Baltimore recover so that it can continue to be one of the best cities in America and a place where all of its citizens can be healthy and succeed."

By Sulaiman Abdur-Rahman

3 minute read

November 14, 2024 | National Law Journal

'We Should Be Pragmatic': Meet the Possible Next FTC Chair

“We’re holding them hostage,” Republican Commissioner Melissa Holyoak of the Federal Trade Commission said of merging parties affected by FTC Chair Lina Khan’s strategic use of consent orders. “This is an extreme abuse of our authority. It is so troubling to me.”

By Sulaiman Abdur-Rahman

4 minute read

November 14, 2024 | National Law Journal

'Health Care Behemoth'?: DOJ Seeks Injunction Blocking $3.3B UnitedHealth Merger Proposal

“The Justice Department will not hesitate to check unlawful consolidation and monopolization in the health care market that threatens to harm vulnerable patients, their families, and health care workers,” U.S. Attorney General Merrick Garland said.

By Sulaiman Abdur-Rahman

3 minute read

November 12, 2024 | National Law Journal

In Lame-Duck Session, US Senate Confirms Illinois Federal Judge on Bipartisan Vote

April M. Perry has become President Joe Biden's 214th successful nominee, with the majority of those appointees being women or persons of color. In 2023, Vice President-elect JD Vance had opposed her nomination as U.S. attorney in Chicago.

By Sulaiman Abdur-Rahman

3 minute read

November 12, 2024 | National Law Journal

DC Judge, Applying 'Loper Bright,' Dismisses Complaint in Medicare Drug-Classification Dispute

U.S. District Senior Judge Beryl A. Howell ruled that federal law “precludes the exercise of jurisdiction to review the agency’s classification of certain oral-only drugs as ‘renal dialysis services’ and its decision to identify [Ardelyx Inc.’s drug Xphozah] as qualifying for such classification.”

By Sulaiman Abdur-Rahman

4 minute read

November 11, 2024 | National Law Journal

'Possible Harm'?: Winston & Strawn Will Appeal Unfavorable Ruling in NASCAR Antitrust Lawsuit

“Although we are disappointed that the preliminary injunction was denied without prejudice and as premature, which we intend to appeal, this denial has no bearing on the merits of our case,” Winston & Strawn partner Jeffrey Kessler said in response to a U.S. District Court ruling in his NASCAR antitrust lawsuit.

By Sulaiman Abdur-Rahman

3 minute read